These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 11979952)
1. [Drugs in development for the treatment of osteoporosis: Incadronate]. Ohsawa M; Soda M; Mizunuma H Nihon Rinsho; 2002 Mar; 60 Suppl 3():538-43. PubMed ID: 11979952 [No Abstract] [Full Text] [Related]
2. [Bisphosphonates: pharmacology and use in the treatment of osteoporosis]. Kishimoto H Nihon Rinsho; 2002 Mar; 60 Suppl 3():350-8. PubMed ID: 11979929 [No Abstract] [Full Text] [Related]
3. [Ipriflavone in the treatment of osteoporosis]. Makita K; Ohta H Nihon Rinsho; 2002 Mar; 60 Suppl 3():359-64. PubMed ID: 11979930 [No Abstract] [Full Text] [Related]
4. [Guideline for treatment of osteoporosis]. Yamamoto I Nihon Rinsho; 2002 Mar; 60 Suppl 3():280-7. PubMed ID: 11979920 [No Abstract] [Full Text] [Related]
5. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Papapoulos SE Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931 [No Abstract] [Full Text] [Related]
6. [Alendronate in the treatment of osteoporosis]. Inaba M Nihon Rinsho; 2002 Mar; 60 Suppl 3():373-80. PubMed ID: 11979932 [No Abstract] [Full Text] [Related]
8. [First choice drug for treatment of osteoporosis and the strategic points for choice of drugs]. Soen S Nihon Rinsho; 2007 Nov; 65 Suppl 9():325-8. PubMed ID: 18159713 [No Abstract] [Full Text] [Related]
9. Issues in designing and testing a "cure" for osteoporosis. Cummings S J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):408. PubMed ID: 15758283 [No Abstract] [Full Text] [Related]
10. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis]. Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488 [No Abstract] [Full Text] [Related]
12. [Osteoporosis in patients with thyroid disease]. Kitahama S; Wada S Nihon Rinsho; 2002 Mar; 60 Suppl 3():451-8. PubMed ID: 11979942 [No Abstract] [Full Text] [Related]
13. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate]. Miki T; Minamide T Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089 [TBL] [Abstract][Full Text] [Related]
14. [Estrogen in the treatment of osteoporosis]. Ohta H Nihon Rinsho; 2002 Mar; 60 Suppl 3():329-39. PubMed ID: 11979926 [No Abstract] [Full Text] [Related]
15. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis]. Ikeda K; Fukagawa M Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664 [No Abstract] [Full Text] [Related]
16. [Prevention of fractures with therapeutic agents for osteoporosis]. Hosoi T Nihon Rinsho; 2004 Feb; 62 Suppl 2():596-601. PubMed ID: 15035197 [No Abstract] [Full Text] [Related]
17. [Parathyroid hormone for osteroporsis: why and who to treat?]. Ferrari S; Rizzoli R Rev Med Suisse; 2005 Oct; 1(35):2272-4, 2276-7. PubMed ID: 16268450 [TBL] [Abstract][Full Text] [Related]
18. Treatment of osteoporosis in men. Orwoll ES Calcif Tissue Int; 2004 Aug; 75(2):114-9. PubMed ID: 15383924 [No Abstract] [Full Text] [Related]
19. [Drugs in development for the treatment of osteoporosis:Raloxifene]. Taga M Nihon Rinsho; 2002 Mar; 60 Suppl 3():572-80. PubMed ID: 11979956 [No Abstract] [Full Text] [Related]